ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1199

Improving Rates of Cervical Cancer Screening and HPV Vaccination in Patients with Lupus

Nancy Desai1, Hanni Menn-Josephy 1, Ramon Bonegio 1, Christina Lam 1, Anna Kancharla 1 and Michael York 1, 1Boston Medical Center, Boston

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Cancer, Lupus, prevention, screening and quality improvement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Measures Of Healthcare Quality Poster II: Improving Care

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with lupus have higher rates of cervical dysplasia and pre-malignant cervical lesions. At our institution, an urban referral center for patients with lupus, rates of HPV vaccination and cervical cancer screening were unknown. The aim of our quality improvement project was to determine the rate of HPV vaccination completion and cervical cancer screening compliance among the lupus patients seen in our institution as well as to implement a process to increase patient education and improve both rates within the outpatient rheumatology, nephrology and dermatology clinics over three months.  

Methods:

Using administrative records, all patients with a diagnosis of lupus seen in the clinics over a 3-year period were identified, of whom 11.4% were male and 88.6% female. A chart review of 332 patients was performed by a single physician to determine the rate of HPV vaccination completion and the rate of compliance with cervical cancer screening. We implemented a system to flag providers through the electronic health record regarding streamlined access to vaccination and facilitating referral for screening exams. Patients were also provided educational brochures about their increased risk of developing cervical lesions, recommended screening and HPV vaccination guidelines. Three months after implementing these processes, we re-evaluated the rates of HPV vaccination and cervical cancer screening.

Results: Prior to the intervention, 41.6% of lupus patients had received HPV vaccination, which was 24.4% lower than the national average for the general population. Cervical cancer screening was 43.8% pre-intervention, which was 32.2% lower than the national average. After implementing the system to flag providers and increase patient education, we were able to improve these rates. Over three months, 71.8% of all patients seen in the clinics were provided education and 38.5% of eligible patients were appropriately referred to either their PCP or to Gynecology to complete cervical cancer screening. Post-intervention, the HPV vaccination rate increased from 41.6% to 58.3% and cervical cancer screening increased from 43.8% to 50%, both of which remained below the national average.

Conclusion: By raising awareness amongst providers in rheumatology, nephrology and dermatology and by implementing processes to facilitate HPV vaccination and cervical cancer screening, rates for both increased. However, rates are still below the national averages for the general population.  Further work is needed to improve rates of cervical cancer screening and HPV vaccination in lupus, given the increased risk of cervical dysplasia.


Lupus figure 1

Figure 1. Rates of HPV vaccination and pap smears among lupus patients at our institution and in the general US population


Lupus figure 2

Figure 2. A run chart representing percent of lupus patients seen in outpatient rheumatology, nephrology, and dermatology clinics that were provided educational materials on cervical cancer screening and HPV vaccination.


Disclosure: N. Desai, None; H. Menn-Josephy, Advance Medical Ltd., 5, Aurinia pharmaceuticals, 6, Mallinckrodt pharmaceuticals, 6; R. Bonegio, None; C. Lam, Biogen, 2; A. Kancharla, None; M. York, None.

To cite this abstract in AMA style:

Desai N, Menn-Josephy H, Bonegio R, Lam C, Kancharla A, York M. Improving Rates of Cervical Cancer Screening and HPV Vaccination in Patients with Lupus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/improving-rates-of-cervical-cancer-screening-and-hpv-vaccination-in-patients-with-lupus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improving-rates-of-cervical-cancer-screening-and-hpv-vaccination-in-patients-with-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology